Sexual Rehabilitation: The Role of the Radiation Oncology Nurse

Article

Combined pelvic radiation therapy and intrauterine brachytherapy are frequently administered for locally advanced cervical and vaginal cancer. These therapies result in sexual dysfunction, namely vaginal shortening and decreased lubrication induced by fibrosis, stenosis, and mucosal atrophy.1-3 Vaginal dilator use is recommended to counter these untoward effects, yet many women fail to use this intervention. It is often perceived as intrusive, embarrassing, and foreign to usual measures of self-care. Researchers in the Netherlands undertook a prospective, longitudinal pilot study whereby four oncology nurses were trained to conduct an educational intervention with gynecologic patients undergoing pelvic radiation therapy and brachytherapy.4 The nurses received education from a number of interdisciplinary colleagues (i.e., sex therapists, psychologists, radiation, and gynecologic oncologists) and this education was delivered via lecture, role play, and group discussion. A treatment manual was developed for the nurses and they received monthly, 2-hour group supervision from the psychologists/sexual therapists during the duration of the study. Additionally, an educational booklet was developed for patients specific to sexual compromise associated with treatment. Outcome measures included frequency of dilator use, sexual functioning, and sexual, psychological, and relational distress measured at baseline, 1, 6, and 12 months post-therapy. Of those who completed the longitudinal assessment, sexual function improved between 1 and 6 months with further improvement evidenced at 1 year following treatment. Nurse-led sexual rehabilitation interventions which include instruction on dilator use, discussion of sexual issues, anxieties and coping responses during recovery, proved advantageous to patients participating in this pilot study. This research offers testimony to the efficacy of nurse-driven interventions to manage the treatment-specific sequelae associated with radiation therapy. Should these interventions be integrated into standardized care plans for women with gynecologic malignancies receiving radiation therapy? The answer is not yes, but how. References

  • Jensen PT, Froeding LP. Pelvic radiotherapy and sexual functioning in women. Transl Androl Urol. 2015 Apr; 4(2): 186–205.
  • Le Borgne G, Mercier M, Woronoff AS, et al. Quality of life in long-term cervical cancer survivors: a population-based study. Gynecol Oncol. 2013 Apr;129(1):222-8.
  • Brand A, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):288-93.
  • Bakker RM, Mens JW, de Groot HE, et al. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer. Support Care Cancer. 2017 Mar;25(3):729-737.

 

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024
Article

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Nab-Sirolimus Yields Sustained Responses in Gynecologic Sarcomas

March 20th 2024
Article

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024
Article

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.